Follow us on twitter Follow us on X

Potential preventive properties of GLP‑1 receptor agonists against prostate cancer: a nationwide cohort study – published online 03/08/2023

Skriver graphical abstract

Charlotte Skriver, Søren Friis, Lotte B. Knudsen, Andrei‑Mircea Catarig, Alice J. Clark, Christian Dehlendorff, Lina S. Mørch

Findings from preclinical and epidemiological studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may protect against prostate cancer, but the evidence is inconclusive. In this issue, Skriver et al (https://doi.org/10.1007/s00125-023-05972-x) report findings from a large population-based study employing data from Danish nationwide prescription, cancer, health and administrative registries. Using these data, the authors examined the risk of prostate cancer in a large sample of men aged ≥50 years with diabetes who commenced use of GLP-1RAs or basal insulin during 2007–2019. They show that men treated with GLP-1RAs had a lower incidence of prostate cancer compared with men treated with basal insulin. This association was observed particularly among older men (≥70 years) and men with cardiovascular disease. The authors conclude that their results may indicate that GLP-1RA use could have protective properties against prostate cancer but that further studies are needed to confirm these findings.

All News
Top